February 06, 2026

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir / Madam,

Sub: Completion of US FDA Inspection at Unit III of Eugia Pharma Specialities Ltd., Pashamylaram (our wholly owned subsidiary) – Reg.,

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The United States Food and Drug Administration (US FDA) inspected Unit-III, a Formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the Company, situated at Phase-III, TSIIC, EPIP, IDA, Pashamylaram, Patancheru Revenue Mandal, Sangareddy District, 502307, Telangana, from January 27 to February 06, 2026.

The inspection concluded with 11 observations. The observations are procedural in nature and will be responded to within the stipulated time.

The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe. We will keep the stock exchanges informed if there is any further information relating to the above in the future.

Please take the above information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.02.06 18:12:30 +05'30'

B. Adi Reddy
Company Secretary

Encl.: Annexure

Annexure

Sr. No.	Particulars	Details
1	Name of the authority	US Food and Drug Administration (US FDA), USA
2	Nature and details of the action(s) taken, initiated or order(s) passed by the Authority	The US FDA inspected Unit-III, a Formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the Company, situated at Phase-III, TSIIC, EPIP, IDA, Pashamylaram, Patancheru Revenue Mandal , Sangareddy District, 502307, Telangana, from January 27 to February 06, 2026.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	February 06, 2026
4	Details of the violation(s)/ contravention(s) committed or alleged to be committed	The inspection concluded with 11 observations. The observations are procedural in nature and will be responded to within the stipulated time.
5	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no impact on the Company's financials or operations due to the said action.

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.02.06 18:12:55 +05'30'